Promise of sodium-glucose co-transporter-2 inhibitors in heart failure with mildly reduced ejection fraction.

However, when individual outcomes were assessed, sotagliflozin did not reach statistical significance in lowering the rate of CV death (10.6 in the sotagliflozin group vs. 12.5 in the placebo; HR, 0.84; 95% CI, 0.58–1.22); this may be ascribed to inadequate power of the trial due to loss of funding and early termination.

also in 111,027 other papers